Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Schiff

Showing results (51-60 of 83) with videos related to

Pageof 9
Sort By:
Plos Biology|January 26, 2016
Correction: A Novel Role for the TIR Domain in Association with Pathogen-Derived ElicitorsTessa M Burch-Smith, Michael Schiff, Jeffrey L Caplan, et al.
Arthritis and Rheumatism|November 22, 2012
Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized studyMichael E Weinblatt, Michael Schiff, Robert Valente, et al.
Annals of the Rheumatic Diseases|August 22, 2013
Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trialMichael Schiff, Michael E Weinblatt, Robert Valente, et al.
Arthritis Research & Therapy|December 4, 2019
Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugsVibeke Strand, Michael Schiff, Namita Tundia, et al.
Surgical Endoscopy|December 21, 2006
The introducer technique is the optimal method for placing percutaneous endoscopic gastrostomy tubes in head and neck cancer patientsJason M Foster, Peter Filocamo, Hector Nava, et al.
Arthritis Research & Therapy|June 11, 2020
Correction to: Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXTVibeke Strand, Janet Pope, Namita Tundia, et al.
Head & Neck|November 8, 2024
Radiation-Induced Pharyngeal Necrosis and Cervical Spine Osteoradionecrosis in Patients With Oropharyngeal Squamous Cell CarcinomaDiana S Shaari, Danielle A Kapustin, Michelle Yoon, et al.
Clinical and Experimental Rheumatology|May 18, 2021
Analysis of patients with rheumatoid arthritis and higher radiographic progression: association of very high radiographic progression but not of intermediately high with worsening of patient-related outcomesReto Thalmann, Johannes von Kempis, Armin Zgraggen, et al.
RMD Open|June 7, 2019
Low rates of radiographic progression of structural joint damage over 2 years of baricitinib treatment in patients with rheumatoid arthritisDesirée van der Heijde, Michael Schiff, Yoshiya Tanaka, et al.
Arthritis Research & Therapy|December 10, 2019
Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXTVibeke Strand, Janet Pope, Namita Tundia, et al.
Pageof 9

Showing results (51-60 of 83) with videos related to

Sort By:
Pageof 9
Plos Biology|January 26, 2016
Correction: A Novel Role for the TIR Domain in Association with Pathogen-Derived ElicitorsTessa M Burch-Smith, Michael Schiff, Jeffrey L Caplan, et al.
Arthritis and Rheumatism|November 22, 2012
Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized studyMichael E Weinblatt, Michael Schiff, Robert Valente, et al.
Annals of the Rheumatic Diseases|August 22, 2013
Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trialMichael Schiff, Michael E Weinblatt, Robert Valente, et al.
Arthritis Research & Therapy|December 4, 2019
Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugsVibeke Strand, Michael Schiff, Namita Tundia, et al.
Surgical Endoscopy|December 21, 2006
The introducer technique is the optimal method for placing percutaneous endoscopic gastrostomy tubes in head and neck cancer patientsJason M Foster, Peter Filocamo, Hector Nava, et al.
Arthritis Research & Therapy|June 11, 2020
Correction to: Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXTVibeke Strand, Janet Pope, Namita Tundia, et al.
Head & Neck|November 8, 2024
Radiation-Induced Pharyngeal Necrosis and Cervical Spine Osteoradionecrosis in Patients With Oropharyngeal Squamous Cell CarcinomaDiana S Shaari, Danielle A Kapustin, Michelle Yoon, et al.
Clinical and Experimental Rheumatology|May 18, 2021
Analysis of patients with rheumatoid arthritis and higher radiographic progression: association of very high radiographic progression but not of intermediately high with worsening of patient-related outcomesReto Thalmann, Johannes von Kempis, Armin Zgraggen, et al.
RMD Open|June 7, 2019
Low rates of radiographic progression of structural joint damage over 2 years of baricitinib treatment in patients with rheumatoid arthritisDesirée van der Heijde, Michael Schiff, Yoshiya Tanaka, et al.
Arthritis Research & Therapy|December 10, 2019
Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXTVibeke Strand, Janet Pope, Namita Tundia, et al.
Pageof 9